Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression
暂无分享,去创建一个
J. Pariente | F. Pasquier | F. Lamari | M. Didic | S. Bombois | A. Brice | V. Deramecourt | D. Wallon | S. Auvin | D. Saracino | M. Houot | C. Azuar | D. Bonnefont-Rousselot | S. Auriacombe | D. Rinaldi | I. Ber | C. Boutoleau-Bretonnière | F. Clot | F. Fluchère | B. Rucheton | Y. Nadjar | R. Levy | D. Schlemmer | B. Dubois | W. Khrouf | Joana Vítor | Marie Huynh | Evelyne Heng | Imen Ben Younes
[1] Ying Sun,et al. PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[2] J. Pariente,et al. Brain Metabolic Profile in Presymptomatic GRN Carriers Throughout a 5-Year Follow-up , 2022, Neurology.
[3] Robert V Farese,et al. Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis , 2022, Nature Communications.
[4] Jennifer M. Nicholas,et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia , 2022, Nature Medicine.
[5] B. Boeve,et al. Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations , 2022, The Lancet Neurology.
[6] J. Pariente,et al. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.
[7] Sheng-Yang M. Goh,et al. Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration , 2021, Neurology.
[8] C. Lourenço,et al. Quantification of lysosphingomyelin and lysosphingomyelin-509 for the screening of acid sphingomyelinase deficiency , 2021, Orphanet Journal of Rare Diseases.
[9] N. Seyfried,et al. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations , 2020, Acta Neuropathologica Communications.
[10] N. Seyfried,et al. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations , 2020, Acta neuropathologica communications.
[11] G. Lopez,et al. Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism. , 2020, Trends in molecular medicine.
[12] Haiyuan Yu,et al. Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice , 2020, EMBO reports.
[13] P. Worley,et al. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[14] B. Dubois,et al. Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience , 2020, Neurobiology of Aging.
[15] G. Frisoni,et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[16] C. Duyckaerts,et al. Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. , 2019, Brain : a journal of neurology.
[17] Nick C Fox,et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study , 2019, The Lancet Neurology.
[18] Nick C Fox,et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study , 2019, The Lancet Neurology.
[19] D. Krainc,et al. Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. , 2019, Human molecular genetics.
[20] David T. Jones,et al. Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium , 2019, Alzheimer's & Dementia.
[21] L. Grinberg,et al. NEURONAL SORTING AND DEGRADATION OF TAU BY THE ENDOLYSOSOMAL PATHWAY AND RAB35 IN HIPPOCAMPAL PATHOLOGY , 2019, Alzheimer's & Dementia.
[22] A. Rolfs,et al. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease , 2019, International journal of molecular sciences.
[23] M. Plebani,et al. Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study , 2019, Clinical chemistry and laboratory medicine.
[24] C. Craik,et al. Progranulin Stimulates the In Vitro Maturation of Pro-Cathepsin D at Acidic pH. , 2019, Journal of molecular biology.
[25] Ying Sun,et al. Progranulin deficiency leads to reduced glucocerebrosidase activity , 2019, bioRxiv.
[26] S. Illarioshkin,et al. Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations , 2018, Movement disorders : official journal of the Movement Disorder Society.
[27] D. Ory,et al. A HILIC-MS/MS method for simultaneous quantification of the lysosomal disease markers galactosylsphingosine and glucosylsphingosine in mouse serum. , 2018, Biomedical chromatography : BMC.
[28] Yuehong Chen,et al. Molecular regulations and therapeutic targets of Gaucher disease. , 2018, Cytokine & growth factor reviews.
[29] Tuancheng Feng,et al. The lysosomal function of progranulin, a guardian against neurodegeneration , 2018, Acta Neuropathologica.
[30] P. Latour,et al. Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders , 2018, Journal of Inherited Metabolic Disease.
[31] D. Krainc,et al. Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients , 2017, Human molecular genetics.
[32] P. Latour,et al. LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease , 2017, PloS one.
[33] W. Seeley,et al. Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations , 2017, Nature Communications.
[34] Param Priya Singh,et al. Progranulin, lysosomal regulation and neurodegenerative disease , 2017, Nature Reviews Neuroscience.
[35] Susan L Cotman,et al. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis , 2017, Science Translational Medicine.
[36] Haiqun Lin,et al. Glucosylsphingosine is a key biomarker of Gaucher disease , 2016, American journal of hematology.
[37] G. Poda,et al. Structure of Human Acid Sphingomyelinase Reveals the Role of the Saposin Domain in Activating Substrate Hydrolysis. , 2016, Journal of molecular biology.
[38] Ying Sun,et al. Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin , 2015, The Journal of cell biology.
[39] M. Nishihara,et al. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice , 2014, Acta neuropathologica communications.
[40] E. Kremmer,et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis , 2014, Acta Neuropathologica.
[41] P. Tsai,et al. A hexanucleotide repeat expansion in C9ORF72 causes familial and sporadic ALS in Taiwan , 2012, Neurobiology of Aging.
[42] Katherine R. Smith,et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. , 2012, American journal of human genetics.
[43] David Heckerman,et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.
[44] M. V. van Breemen,et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. , 2011, Blood.
[45] Bruce L. Miller,et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.
[46] Nick C Fox,et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.
[47] L. Petrucelli,et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. , 2010, The American journal of pathology.
[48] A. Bateman,et al. The granulin gene family: from cancer to dementia , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.
[49] G. Binetti,et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration , 2008, Neurology.
[50] C. Duijn,et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21 , 2006, Nature.
[51] S. Melquist,et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.
[52] C. Morales,et al. The Lysosomal Trafficking of Acid Sphingomyelinase is Mediated by Sortilin and Mannose 6‐phosphate Receptor , 2006, Traffic.